Navigation Links
Will lung cancer recur? A genetic test may provide the answer
Date:5/19/2008

ATS 2008, TORONTOThe goal of developing reliable genetic tests to guide lung cancer treatment has taken a step forward. Researchers at Columbia University recently evaluated the ability of five high-risk genetic profiles, or signatures, to predict the likelihood that cancer would recur in patients whose non-small cell lung cancer was caught early and surgically removed. They will present their findings at the American Thoracic Societys 2008 International Conference in Toronto on Tuesday, May 20.

Non-small cell lung cancer, which accounts for about 80 percent of all lung cancers, has a high rate of recurrence even when treated early, said lead researcher William Bulman, M.D. If we knew specifically in which patients the cancer was likely to come back, we could recommend more aggressive therapy to those patients. Dr. Bulman noted that genetic signatures for breast cancer are already commercially available and are used by physicians to guide treatment recommendations.

Dr. Bulman and his colleagues, Drs. Charles Powell and Alain Borczuk, tested five survival gene signatures in 21 patients, with squamous or adenocarinoma tumors who were followed for up to two years after their surgery. The accuracy of the tested signatures ranged from 40 to 80 percent and varied with the type of tumor. A 42-gene signature, for instance, was 82 percent accurate in predicting survival with lung adenocarcinoma, but only 70 percent accurate in predicting survival with squamous cell carcinoma.

Lung cancer is a heterogeneous disease, and information captured in these tests helps to distinguish tumors in terms of clinical outcomes. explained Dr. Bulman. Our findings not only indicate that genetic signatures have clinical utility in personalizing the treatment of lung cancer, but also that it may be necessary to use different gene-based risk predictors with different tumor subtypes.

Dr. Bulman noted that this research is part of a larger effort to understand the biological basis for why some early stage lung cancers progress and metastasize and why some do not. He added that he and his colleagues are planning to test these genetic signatures in new cohorts of patients for the purposes of targeting patients at high risk for recurrence.


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Blood test for lung cancer may be possible
2. Petition Seeking a Cancer Warning on Cosmetic Talc Powder Products
3. Protein Helps ID Thyroid Cancer Nodules
4. Kidney Cancers More Likely to Be Diagnosed Early
5. Traditional herbal medicine kills pancreatic cancer cells, Jefferson researchers report
6. Majority of kidney cancers diagnosed at earliest stage
7. New data show benefit of finasteride in preventing prostate cancer
8. Cellvizio(R) Confocal Microscopy Improves ERCP Bile Duct Cancer Detection, According to New Study Presented at DDW
9. Prostate Cancer Vaccine Looks Promising in Early Trial
10. Outcomes Similar for Laparoscopic, Open Colon Cancer Surgeries
11. M. D. Anderson nurse addresses lymphedema in breast cancer patients and survivors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Quality Insights beginning January 1, 2017. The name change aligns the entire ... measuring and improving health care quality. , “We are very proud of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... Dec. 8, 2016 Australia Glaucoma Surgery ... GlobalData,s new report, "Australia Glaucoma Surgery Devices Market ... the Australia Glaucoma Surgery Devices market. The report ... (in units) and average prices (USD) within market ... also provides company shares and distribution shares data ...
(Date:12/8/2016)... -- KEY FINDINGS The global medical lifting ... reasons for growth of the medical lifting sling market ... diseases, high recovery cost of injuries and government initiatives ... sling refers to an assistive device that helps caregiver ... to the lift and hold the patient. It is ...
Breaking Medicine Technology: